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Recent studies suggest that hereditary prostate cancer is a complex disease involving multiple susceptibility genes
and variable phenotypic expression. While conducting a genomewide search on 162 North American families with
3 members affected with prostate cancer (PRCA), we found evidence for linkage to chromosome 20q13 with
two-point parametric LOD scores 11 at multiple sites, with the highest two-point LOD score of 2.69 for marker
D20S196. The maximum multipoint NPL score for the entire data set was 3.02 ( ) at D20S887. On theP = .002
basis of findings from previous reports, families were stratified by the presence ( ) or absence ( ) ofn = 116 n = 46
male-to-male transmission, average age of diagnosis (!66 years, ; 66 years, ), and number of affectedn = 73 n = 89
individuals (!5, ; 5, ) for further analysis. The strongest evidence of linkage was evident with then = 101 n = 61
pedigrees having !5 family members affected with prostate cancer (multipoint NPL 3.22, ), a laterP = .00079
average age of diagnosis (multipoint NPL 3.40, ), and no male-to-male transmission (multipoint NPLP = .0006
3.94, ). The group of patients having all three of these characteristics ( ) had a multipoint NPLP = .00007 n = 19
score of 3.69 ( ). These results demonstrate evidence for a PRCA susceptibility locus in a subset of familiesP = .0001
that is distinct from the groups more likely to be linked to previously identified loci.
Introduction
Prostate cancer is one of the most common human can-
cers, occurring in as many as 15% of men in the United
States (Kosary et al. 1995). While the majority of cases
of prostate cancer are sporadic, it has long been rec-
ognized that familial clustering exists, with an increased
relative risk occurring in relatives of affectedmen (Woolf
1960; Cannon et al. 1982; Meikle and Stanish 1982;
Carter et al. 1990; Steinberg et al. 1990; Spitz et al. 1991;
Goldgar et al. 1994; Whittemore et al. 1995). Segre-
gation analysis of prostate cancer suggests the presence
of at least one dominant susceptibility locus that may
account for up to 10% of all prostate cancers (Carter
et al. 1992; Schaid et al. 1998). Although genetic linkage
analysis is a powerful technique for the identification of
disease susceptibility loci, it is confounded by several
factors in prostate cancer families. These include a late
age at onset, a high phenocopy rate, and a lack of dis-
tinguishing features between the hereditary and sporadic
forms of the disease.
In spite of such problems, two putative prostate can-
cer–susceptibility loci (HPC1 [MIM601518] andPCAP
[MIM 602759]) (Smith et al. 1996; Berthon et al. 1998),
plus a rare prostate cancer–brain cancer–susceptibility
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locus (CAPB [MIM 603688]) (Gibbs et al. 1999b), have
been localized to regions on chromosome 1 through
linkage studies of high risk prostate cancer families. In
addition to these candidate regions on chromosome 1,
evidence for linkage of a prostate cancer susceptibility
locus to Xq27-28 (HPCX [MIM300147]) has also been
reported in a combined study population (Xu et al.
1998). Although the initial report of linkage to the
HPC1 (1q24-25) region indicated that as many as 34%
of familial PRCA (MIM 176807) may be linked to this
region (Smith et al. 1996), a subsequent pooled analysis
of 772 families showed the actual proportion to be
much lower, probably ∼6% (Xu et al. 2000). Studies
have shown that families meeting the three crite-
ria—male-to-male transmission, early average age at di-
agnosis (!65 years), and 5 affected family mem-
bers—are more likely to be linked to HPC1 (Gro¨nberg
et al. 1997; Xu et al. 2000).
Since the initial report of HPC1, there have been sev-
eral studies aimed at confirming linkage to this region.
Four studies have shown weak evidence of linkage using
nonparametric methods (Cooney et al. 1997; Hsieh et
al. 1997; Neuhausen et al. 1999; Berry et al. 2000),
whereas three other studies have shown no evidence of
linkage to HPC1 (McIndoe et al. 1997; Berthon et al.
1998; Eeles et al. 1998). For the PCAP (1q42.2-43)
region, Berthon et al. (1998) estimated that as many as
40%–50% of their families might be linked. However,
three subsequent studies of this region found no signif-
icant evidence for linkage with either parametric or non-
parametric methods (Gibbs et al. 1999a; Whittemore et
al. 1999; Berry et al. 2000). Therefore, although a mi-
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nority of families affected by prostate cancer may be
linked to the PCAP region, the proportion is likely con-
siderably less than 40%. The CAPB (1p36) region in
families with both brain and prostate cancers was not
confirmed in a followup study (Berry et al. 2000). To
date, there has been one report attempting to confirm
the linkage to the HPCX region (Lange et al. 1999),
which, in the original report, was thought to account
for an estimated 16% of familial prostate cancer cases
(Xu et al. 1998). Lange et al. (1999) reported positive
LOD scores over a 30-cM region containing HPCX,
with the subset of cases with no evidence of male-to-
male transmission and with early onset of disease (65
years) contributing the greatest evidence for linkage.
Overall, these four loci appear to account for only a
minority of familial prostate cancer cases, and none of
the putative genes have been identified so far. In an
attempt to identify additional loci, we initiated a ge-
nomewide search on 162 families affected by prostate
cancer. Utilizing both parametric and nonparametric
analyses, we present evidence for a genetic-susceptibility
locus on chromosome 20, which we have calledHPC20.
Materials and Methods
Ascertainment of Families
Families were ascertained through the Mayo Clinic
radical prostatectomy database. All men who received
a radical prostatectomy, in the Department of Urology,
for clinically localized prostate cancer or who received
radiation therapy, in the Division of Radiation Oncol-
ogy, were sent a family cancer-history survey (Schaid et
al. 1998). A total of 12,675 surveys were sent on two
separate occasions: March 1995 and July 1997. From
these surveys, 199 high-risk families were identified.
More-detailed family histories were obtained over the
telephone and 3–4-generation pedigrees were con-
structed. From this group, a total of 162 families having
a minimum of three men affected with prostate cancer
were collected for linkage studies. For 118 pedigrees, the
minimum criteria was met with the use of first-degree
relatives alone, 24 pedigrees with first- and second-de-
gree relatives, and 20 pedigrees with first- and third-
degree relatives. All but one of these families are white;
the remaining family is Hispanic. There were no black
families. For 82 of the families, blood was collected from
as many family members as possible, including a mini-
mum of three living affectedmen and unaffected siblings.
The majority of the living affected men come from sib-
lings and cousins, with a smaller proportion from neph-
ews. Rarely were fathers and uncles available for anal-
ysis. For the remaining 80 families that met the selection
criteria, blood was collected on 73 affected sib pairs and
7 other types of affected relative pairs, since the other
affected family members were deceased. All men who
contributed a blood specimen and who had prostate can-
cer had their cancers verified by review of medical re-
cords, particularly pathology reports. We were unable
to review medical records for deceased individuals. The
average age of diagnosis per pedigree was 66.5 years
(range 47–77 years), with 73 pedigrees having an av-
erage age at diagnosis !66 years. There were 61 pedi-
grees with 5 affected men. The average number of
affected men per pedigree was 4.4 (range 3–11), the
average number of affected men with blood specimens
per pedigree was 2.8 (range 2–7), and the average num-
ber of total blood specimens per pedigree was 3.7 (range
2–12). The characteristics of all families and the three
stratified groups used for the linkage analysis (male-to-
male vs. no male-to-male transmission, average age at
diagnosis !66 years vs. 66 years, and !5 affected men
per family vs.5) are illustrated in table 1. The research
protocol and informed consent forms were approved by
the Mayo Clinic Institutional Review Board. DNA was
isolated from peripheral blood lymphocytes using stan-
dard methods.
Genotyping
Markers used for the genotyping were from the ABI
Prism Linkage Mapping Set Version 2 (PE Applied Bios-
ystems). Additional markers were derived from the Ge-
nome Database (Johns Hopkins University School of
Medicine). Forward primers were labeled with phos-
phoramidite dyes. Each 15-ml reaction contained 25 ng
of genomic DNA, 200 mM dNTPs, 8mM each primer,
0.5 U AmpliTaq Gold (PE Biosystems), and 1.5–2.5 mM
MgCl2. Reactions were cycled in either a Perkin-Elmer
GeneAmp PCR System 9600 or an MJR Tetrad Cycler
as follows: 10 minutes at 95C, then 35 cycles of 30 s
at 95C, 30 sec at 58C or 55C, 30 s at 72C; followed
by an extension step of 10 min at 72C. PCR reactions
were held at 5C until analysis. The PCR products were
resolved on a 5% denaturing polyacrylamide gel and
detected using an ABI 377 DNA sequencer. Genotypes
were analyzed using ABI Genescan 2.1 and ABI Geno-
typer 2.0.
Linkage Analysis
We performed genetic linkage analyses by both par-
ametric and model-free methods. The parametric two-
point LOD scores were computed by the LINKAGE
package (FASTLINK) using an assumed prostate can-
cer–susceptibility allele frequency of .003 and an auto-
somal dominant model. The model used for this analysis
is the same as that used by Smith et al. (1996) in the
first reported linkage finding for hereditary prostate can-
cer. In summary, this model assumed a 15% phenocopy
rate; affected men had penetrances of .001 and 1.0 for
noncarriers and carriers, respectively; the lifetime pen-
etrances for unaffected men of age 175 years were 16%
84 Am. J. Hum. Genet. 67:82–91, 2000
Table 1
Characteristics of the 162 Families Utilized for the Linkage Analysis in This Study
Families
No. of
Families
No. of
Affected
Individuals
Genotyped
No. of
Unaffected
Individuals
Genotyped
Average No.
(Range) of
Individuals
Affected/
Family
Average No.
(Range) of
Affected
Individuals
Genotyped/
Family
Average Age
at Diagnosis
(SD)
of Affected
Individualsa
All 162 447 160 4.4 (3–11) 2.8 (2–7) 66.5 (4.7)
Male-to-male transmission 116 325 116 4.7 (3–10) 2.8 (2–7) 66.7 (4.5)
No male-to-male transmission 46 122 44 3.7 (3–11) 2.7 (2–5) 66.2 (5.4)
Age at diagnosis !66 years 73 192 62 4.4 (3–10) 2.6 (2–7) 62.4 (3.2)
Age at diagnosis 66 years 89 255 98 4.5 (3–11) 2.9 (2–7) 69.9 (2.6)
!5 affected members 101 244 48 3.4 (3–4) 2.4 (2–4) 66.3 (5.1)
5 affected members 61 203 112 6.2 (5–11) 3.3 (2–7) 67.0 (4.2)
a SD = standard deviation of mean age per pedigree.
for noncarriers and 63% for carriers; and unaffected
men of age !75 years and all women were not infor-
mative (i.e., unknown phenotype). A similar recessive
model was used, except that the susceptibility-allele fre-
quency was set at 0.077, giving the same population
frequency of high-risk subjects as the dominant model,
and the penetrance for heterozygous carriers was re-
duced to that of the noncarriers. Linkage in the presence
of heterogeneity was assessed using Smith’s admixture
test for heterogeneity (HOMOG program). Multipoint
LOD scores were computed by the GENEHUNTERpro-
gram. As the inheritance of prostate cancer is complex,
we also performed multipoint identical-by-descent
model-free linkage analyses for affected pedigree mem-
bers, using the NPL Z-all statistic in theGENEHUNTER
program. Marker-allele frequencies were estimated from
the data set.
Results
An analysis of the initial markers used for chromosome
20 provided suggestive evidence of linkage to chromo-
some 20q13, with two-point parametric LOD scores 11
at multiple markers. The highest two-point LOD score
was 2.69 for marker D20S196 at recombination fraction
.20. A single marker on 20p, D20S186, had a two-point
LOD score 11 (LOD score 1.26 at recombination frac-
tion .20). In an effort to further refine the area of linkage,
five additional markers in the 20q13 region (D20S109,
D20S120, D20S149, D20S887, and D20S893) were an-
alyzed, creating an average density map interval of 3.8
cM. The two-point parametric LOD scores for all of the
markers are shown in table 2. With the additional mark-
ers, the peak two-point LOD score remained at
D20S196.
Multipoint analyses also provided evidence of linkage
to this region on chromosome 20. The maximum mul-
tipoint NPL score was 3.02 ( ) at D20S887. As-P = .002
suming homogeneity, multipoint LOD scores were all
negative. However, after allowing for linkage hetero-
geneity, the heterogeneity LOD score (HLOD) was 1.08
( ), with an estimated 12% of the families dem-P = .026
onstrating linkage.
Because hereditary prostate cancer is likely a heter-
ogeneous disease, and because prior studies have sug-
gested critical subsets to increase homogeneity (Xu et
al. 2000), families were reevaluated for linkage after
stratification according to the following criteria: the
presence ( ) or absence ( ) of male-to-malen = 116 n = 46
transmission, average age at diagnosis (!66 years, n =
; 66 years, ), and number of affected indi-73 n = 89
viduals (!5, ; 5, ). More detailed char-n = 101 n = 61
acteristics of these stratified groups are illustrated in
table 1. Results of the two-point analysis at D20S196
is presented in table 3 while results from the multipoint
analysis (both parametric and nonparametric) are pre-
sented in table 4. The pedigrees with no male-to-male
transmission had a maximum two-point LOD score of
3.38 at a recombination fraction 0.10 for D20S196 (ta-
ble 3). The families with !5 affected individuals had a
maximum two-point LOD score of 2.26 at D20S196,
whereas those with a later average age at diagnosis (66
years) had a maximum two-point LOD score of 2.67
at this same marker. The subset ( ) that met alln = 19
three criteria of no male-to-male transmission, !5 af-
fected individuals, and later average age at onset (66
years) had a maximum two-point LOD score of 3.56
at recombination fraction 0 for D20S196.
Multipoint analyses showed evidence for linkage with
heterogeneity within the various subsets (table 4): no
male-to-male transmission (HLOD 3.61, ,P = .00005
estimated 56% families linked), !5 affected (HLOD
1.51, , estimated 30% families linked), andP = .0083
later average age of diagnosis (HLOD 1.39, ,P = .011
estimated 22% families linked). The 19 families that
met all three criteria had an HLOD of 2.34 ( ),P = .001
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Table 2
Parametric Two-Point LOD Scores for 18 Markers on Chromosome 20 Utilizing Model A for the
Analysis
NO. OF
INFORMATIVE
PEDIGREES MARKER
LOD SCORE AT RECOMBINATION FRACTION
0 .01 .05 .1 .2 .3 .4
159 D20S117 71.94 51.29 25.54 13.67 4.28 1.17 .22
153 D20S889 65.29 46.91 23.52 12.38 3.52 .72 .06
160 D20S115 36.31 25.31 11.51 5.30 .83 .16 .11
161 D20S186 44.13 29.90 11.74 3.70 1.26 1.44 .49
160 D20S112 41.02 28.45 12.23 4.91 .02 .73 .29
161 D20S195 58.06 39.97 17.57 7.75 .93 .46 .26
160 D20S107 34.14 22.18 7.51 1.50 1.79 1.54 .55
161 D20S119 45.43 3.73 12.54 4.78 .23 .85 .34
157 D20S178 44.21 29.99 11.73 3.81 1.00 1.25 .44
156 D20S887 36.82 24.71 9.71 3.04 1.10 1.24 .41
153 D20S109 52.78 35.99 15.38 6.28 .18 .78 .32
160 D20S196 36.90 23.98 7.77 .92 2.69 2.07 .65
159 D20S893 55.44 38.25 16.58 6.82 .17 .89 .36
150 D20S120 46.24 33.36 13.97 5.40 .25 .97 .37
160 D20S100 27.75 17.72 5.80 .99 1.64 1.34 .43
159 D20S149 65.22 44.83 19.58 8.30 .50 .89 .42
157 D20S171 33.54 22.23 8.40 2.61 .79 .88 .28
158 D20S173 47.79 34.48 17.01 8.72 2.19 .28 .04
with an estimated 75% of families linked. The non-
parametric methods also showed significant evidence
for linkage to the 20q13 region in the no male-to-male
transmission group (table 4) (figure 1). For this subset,
the maximum multipoint NPL score was 3.94 (P =
) at D20S887, with a comparable peak (multi-.00007
point NPL 3.89) at D20S893. There was also evidence
of linkage in the subset with !5 affected (maximum
multipoint NPL 3.22, ) and in the later–age-P = .00079
at-diagnosis subset (maximum multipoint NPL 3.40,
). When all three of these criteria were used,P = .0006
the maximum multipoint NPL was 3.69 ( ) atP = .0001
D20S893 (table 4) (figure 1). As can also be seen in
figure 1, there was another, smaller, multipoint NPL
peak on 20p at D20S186. When the groups were strat-
ified, there did not appear to be much difference for
this peak among the stratified groups.
The finding of significant evidence for linkage in the
no male-to-male transmission group, both by paramet-
ric and nonparametric methods, was unanticipated.
However, there are several possible explanations for
such an observation, including the presence of gene-gene
interaction, the presence of recessive rather than dom-
inant inheritance, and the involvement of an imprinted
locus. To further explore the potential interactions of
genes on the X and 20 chromosomes, we used GENE-
HUNTER-PLUS, which allows definition of family-spe-
cific weights (Cox et al. 1999). The NPL scores from
the most likely linked region on the X chromosome (in
the vicinity of HPCX or, in our population, the marker
AFMA113zf5) (Xu et al. 1998) were used to define
weights when we examined linkage for chromosome 20,
and in a complementary fashion, the NPL scores from
the most likely linked region on chromosome 20 (in the
vicinity of D20S196) were used as weights to evaluate
linkage on chromosome X. We have previously dem-
onstrated the presence of linkage in ∼16% of our fam-
ilies at the HPCX region (Xu et al. 1998). Two weight-
ing schemes were evaluated: (1) to emphasize
interaction of genes on X and 20 chromosomes, a
weight of 1 versus 0 used only pedigrees that demon-
strated evidence for linkage to the X chromosome (i.e.,
according to X-NPL 10); and (2) to emphasize linkage
heterogeneity betweenX and 20 chromosomes, aweight
of 0 versus 1 used only pedigrees that demonstrated no
evidence for linkage to the X-chromosome (i.e., ac-
cording to X-NPL0). For all analyses, the exponential
model was used to compute allele-sharing LOD scores
(Kong et al. 1997). These types of analyses were run
for the two subsets of pedigrees with male-to-male
transmission (80 pedigrees) and the subset of pedigrees
without male-to-male transmission (42 pedigrees). Re-
sults from these analyses (data not shown), however,
did not provide evidence for an interaction of the chro-
mosomal regions around D20S196 and around
AFMA113zf5.
To explore the potential overlap between those fam-
ilies linked to HPCX and those linked to a locus on
chromosome 20, we used the program HOMOG3R to
analyze the subset of pedigrees without male-to-male
transmission. This programs allows for a test for linkage
heterogeneity with two measured loci, as well as a third
group of pedigrees not linked to either of the measured
loci. If there is no overlap between families linked to
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Table 3
Maximum Two-Point LOD Scores at D20S196 for the Entire Data
Set and the Four Subsets
Subset n
Dominant
LOD
Recessive
LOD
Full Group 162 2.69 3.11
Number affected:
!5 101 2.26 2.74
5 61 .63 .63
Average age at diagnosis (years):
!66 73 .36 .22
66 89 2.67 3.64
Male-to-male transmission:
Yes 116 .78 .92
No 46 3.38 2.58
Combined criteria:
!5 members affected, age
at diagnosis 66 years, no
male-to-male transmission 19 3.56 3.48
5 members affected,
age at diagnosis !66 years,
male-to-male transmission 25 .15 .16
chromosomes X and 20, then the estimated fraction of
pedigrees linked to these two chromosomes should be
the same, whether we analyze chromosomes 20 and X
together, with the HOMOG3R program, or each chro-
mosome by itself, with the HOMOG program. This, in
fact, was the case. Using the dominant model for chro-
mosome 20, an overall HLOD of 2.55 was observed,
with an estimate of 45% of the pedigrees linked to
chromosome 20, and 10% linked to the X chromosome.
Most of this evidence for linkage heterogeneity came
from chromosome 20, because an HLOD for chro-
mosome 20 adjusted for X linkage was very similar,
2.20. Results for the recessive model were similar, with
an overall HLOD of 2.94 (30% linked to chromosome
20; 15% linked to chromosome X), and an HLOD for
chromosome 20 adjusted for chromosome X of 2.59.
Additionally, our model-free analyses by the NPL scores
were consistent with little overlap of families linked to
both the X and 20 chromosomes. Of the 18 families
that had an NPL score 11 for either D20S196 or
AFMA113zf5, only 1 had an NPL score 11 at both of
these loci.
To further explore the reason for linkage in the no
male-to-male transmission group, we used a recessive
model for the parametric analysis. Overall, the two-
point linkage results for each of the markers provided
similar results compared to the dominant model. The
results of the two-point LOD scores at D20S196 for the
entire data set and the four subsets are illustrated in
table 3. Although the recessive model gave a higher
LOD score than the dominant model for the entire
group, the opposite occurred in the subset withoutmale-
to-male transmission, suggesting that a recessive mech-
anism alone does not explain our linkage results for the
subset without male-to-male transmission. However,
since there is no significant difference in the results for
the dominant versus the recessive model, we are unable
to distinguish between these two modes of inheritance
given our current data.
Discussion
On the basis of the initial two-point parametric linkage
analyses, our data suggested the presence of linkage of
hereditary prostate cancer to a region on chromosome
20q13 near the marker D20S196, with a two-point LOD
score of 2.69. Multipoint model-free allele sharing sup-
ported this finding (NPL score 3.02, ). On fur-P = .002
ther analysis, significant evidence for linkage was dem-
onstrated in the subset of our 46 families without
male-to-male transmission of disease. This subset dem-
onstrated a peak two-point LOD score of 3.38 at
D20S196 and a multipoint heterogeneity LOD score of
3.61, with an estimated 56% of the families linked. It
is important to note that the model-based analyses can
be misleading in terms of the fraction of linked families,
because the penetrance of the putative mutation is un-
known. However, further support for linkage was pro-
vided by the model-free allele sharing statistic with an
NPL score of 3.94 ( ). Importantly, all of theP = .00007
above mentioned analyses have achieved statistical sig-
nificance for this particular subgroup.
Although unanticipated, there are several possible ex-
planations for the finding of linkage in the no male-to-
male group to a region on chromosome 20. Since such
a subgroup would be expected in an X-linked disorder,
one possible explanation is the interaction of a gene on
the X chromosome and a gene on chromosome 20.
Utilizing GENEHUNTER-PLUS and two weighting
schemes, we were unable to find evidence for an inter-
action between the HPCX region and the HPC20 re-
gion. However, there are limitations of this approach
to testing for gene-gene interactions. First, we have lim-
ited power to detect interaction, because of the small
number of pedigrees without male-to-male transmis-
sion. Second, epistasis is implemented in GENE-
HUNTER-PLUS as multiplicative penetrance, and, if
this is the true model without residual correlation of
the phenotypes, then the allele sharing (and NPL scores)
between the X and 20 chromosomes are indepen-
dent—and, hence, epistasis could not be detected with-
out additional factors (such as additional genes) causing
residual correlations. Furthermore, our analyses were
restricted to a 15-cM region at the HPCX locus, which
could miss an interaction with a different, yet distant,
gene on the X chromosome.
A second possibility is the presence of a recessive
rather than a dominant mode of inheritance. Examples
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Table 4
Multipoint Nonparametric NPL Scores and Multipoint Parametric LOD Scores Assuming Both Homogeneity and
Heterogeneity for the Entire Data Set and Four Subsets
SUBSET
NONPARAMETRIC PARAMETRICa
n NPLmax
NPL
P value
Homogeneity
LODmax HLOD
Heterogeneity
Alpha
HLOD
P value
Full Group 162 3.02 .002 36.31 1.08 .12 .026
Number affected:
!5 101 3.22 .00079 13.53 1.51 .30 .0083
5 61 1.26 .107 18.40 1.36 .19 .012
Average age at diagnosis (years):
!66 73 1.82 .036 8.55 1.48 .33 .0089
66 89 3.40 .0006 21.84 1.39 .22 .011
Male-to-male transmission:
Yes 116 1.83 .036 24.57 .17 .05 .306
No 46 3.94 .00007 2.62 3.61 .56 .00005
Combined criteria:
!5 members affected,
age at diagnosis 66 years,
no male-to-male transmission 19 3.69 .0001 1.44 2.34 .75 .001
5 members affected,
age at diagnosis !66 years,
male-to-male transmission 25 1.40 .085 2.52 .90 .39 .041
a Model A.
of autosomal recessive inheritance of increased cancer
risk is provided by the autosomal recessive disorders
ataxia telangiectasia and the RecQ helicase disorders
(Bloom’s syndrome, Werner’s syndrome, Rothmund-
Thomson syndrome) (Savitsky et al. 1995; Ellis et al.
1995; Gray et al. 1997; Kitao et al. 1999). An autosomal
recessive model for hereditary prostate cancer has been
suggested (Monroe et al. 1995). Interestingly, both two-
point and multipoint parametric analyses demonstrated
similar results when compared to the dominant model.
Given our current data, therefore, we are unable to dis-
tinguish between these two modes of inheritance. Based
on simulation studies (not shown), family size will be
a critical factor in distinguishing between these two
models.
Finally, an alternative explanation is the involvement
of an imprinted locus. Of interest, there is both human
and mouse data implicating the 20q13 region as an
imprinting locus (Hall 1990). Most imprinted genes in
the mouse are located within one of nine imprinting
regions distributed across six autosomes (Mouse Im-
printing Data and References Web site)—one of which
is associated with the distal chromosome 2. This region
of mouse chromosome 2 shows striking linkage con-
servation with human chromosome 20 at 20q12-13
(Searle et al. 1989). To date, two imprinted genes have
been identified within the distal chromosome 2 region
in mice: Gnasxl and Nesp (Peters et al. 1999). Fur-
thermore, there is now clinical and biochemical evidence
that GNAS (the human homologue of mouse gene
Gnas), which is mutated in patients with Albright he-
reditary osteodystrophy, is also imprinted (Hayward et
al. 1998; Weinstein and Wu 1999). The presence of an
imprinting locus at the site of linkage of hereditary pros-
tate cancer provides both challenges and opportunities.
Unfortunately, evidence for implicating these alternative
explanations will require additional studies.
Although the strongest evidence for linkage occurred
in a single subgroup, the definition of the stratification
factors were based on prior published reports (Gro¨nberg
et al. 1997; Xu et al. 2000) and were not driven by
exploratory analyses of our own data. This fact can still
inflate the chance of a false-positive finding, and so rep-
lication of our results is warranted. It is also notable
that significant evidence for linkage to the 20q13 locus
was observed in the subsets that are distinct from those
most likely to be linked to theHPC1 and PCAP regions.
Whereas the families with male-to-male transmission,
5 affected, and an average age at diagnosis !66 years
are more likely to be linked to the HPC1 region (Xu et
al. 2000), the strongest evidence for linkage to the
20q13 region was seen in pedigrees meeting the com-
plements of these criteria—that is, those with no male-
to-male transmission, !5 affected, and a later average
age of diagnosis (66 years). The finding of linkage in
the older age at onset might be expected if the pene-
trance of the susceptibility locus was reduced. However,
in spite of the apparent higher age at onset, these fam-
ilies were still selected on the basis of having multiple
affected individuals. In this study, we did not perform
any comparisons between HPC20 and any of the loci
reported for chromosome 1 (Smith et al. 1996; Berthon
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Figure 1 Multipoint NPL scores for the whole data set ( ), and four subsets, on an 18-marker map of chromosome 20. The subsetsn = 162
are: no male-to-male transmission ( ), average age at diagnosis 66 years ( ), !5 affected individuals ( ), and the combinationn = 46 n = 89 n = 101
( ) of no male-to-male transmission, average age of diagnosis 66 years, and !5 affected individuals.n = 19
et al. 1998; Gibbs et al. 1999b) because our families
demonstrated little to no evidence for linkage at these
sites (Berry et al. 2000).
Overall, the two-point parametric LOD scores and
the multipoint NPL scores were consistent with each
other, both with and without stratification. However,
unless heterogeneity was invoked, the parametric mul-
tipoint LOD scores were all negative. Although the mul-
tipoint LOD scores and the multipoint NPL statistics
appear discrepant, it is well known that parametric mul-
tipoint LOD scores tend to be spuriously negative when
the parameters used for analysis (e.g., allele frequency,
mode of inheritance, penetrance) are not correct (Risch
and Giuiffra 1992). This is because nonrecombinant
offspring tend to be misclassified as double recombi-
nants, a rare event, resulting in the disease locus being
“pushed off” the multipoint marker map. In contrast,
the parametric two-point LOD scores tend to be more
robust to model misspecification. Furthermore, theNPL
statistic is ideal for complex traits (Ott 1996). The ad-
vantage of the NPL statistic is that it is not based on
unknown, yet assumed, genetic models, but rather on
the comparison of the observed versus expected sharing
of chromosomal regions identical by descent among af-
fected relatives. For these reasons and because of the
complex nature of prostate cancer, we have relied on
the parametric two-point LOD scores and the multi-
point NPL statistics for our main conclusions.
Linkage to chromosome 20 has been examined in two
previous reports as part of genomewide scans for genetic
susceptibility loci (Smith et al. 1996; Suarez et al. 2000).
In the report by Smith et al. (1996), a marker on chro-
mosome 20 (not identified) demonstrated a two-point
LOD score of 0.5–1. Although these results support the
conclusions of our current study, multiple loci along the
genome demonstrated similar results in the Smith et al.
(1996) report. The region demonstrating the strongest
evidence for linkage in this set of familial was on chro-
mosome 1. In the report by Suarez et al. (2000), on the
other hand, there was no evidence for linkage to the
chromosome 20q region. However, the ascertainment
criteria in the Suarez (2000) report differed from ours.
The minimum selection criteria for their families was
two or more brothers with documented prostate cancer.
Additionally, the strongest evidence for linkage in the
Suarez (2000) report, was found on chromosome arm
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16q. Clearly, additional studies will be required to con-
firm the results of our study. A combined analyses, as
performed for chromosome 1 (Xu et al. 2000), should
provide an ideal mechanism to explore and confirm our
findings.
It is well recognized that prostate cancer is hetero-
geneous and that multiple genetic and environmental
factors are very likely to play a role in its etiology. To
date, genetic linkage analysis has suggested the presence
of four genetic susceptibility loci: HPC1 (1q24-25),
PCAP (1q42.2-43), CAPB (1p36), and HPCX (Xq27-
28). In this study, we present evidence for a fifth prostate
cancer–susceptibility locus at 20q13, for which we pro-
pose the designation HPC20. The heterogeneity of this
disease is underscored by the finding that these five loci
may still account for only a minority (approximately
one-third) of the familial cases. HPC1 and HPCX ap-
pear to account for ∼6% (Xu et al. 2000) and 16% (Xu
et al. 1998) of the cases, respectively, whereas PCAP
and CAPB account for a small fraction. In this study,
we estimate that ∼12% of all our families are linked to
HPC20. Although the accuracy of the estimated per-
centage of families linked to these various chromosomal
regions is questionable, because misspecification of the
genetic model parameters will bias this estimation, it is
clear that multiple genetic factors contribute to the eti-
ology of familial prostate cancer.
In addition to data suggesting 20q13 as an imprinting
region, DNA amplification of this region has frequently
been observed in breast cancer (Kallioniemi et al. 1994),
as well as in other tumor types (Iwabuchi et al. 1995;
Mohapatra et al. 1995; Schlegel et al. 1995; Solinas-
Toldo et al. 1996; Bockmuhl et al. 1997). Increased
expression of genes in this region is likely to contribute
to the progression—and possibly to the develop-
ment—of various cancers, including prostate cancer. A
number of genes have beenmapped to the 20q13 region,
resulting in many possible candidates for a prostate can-
cer–susceptibility gene. We are currently examining
these genes for their potential involvement in hereditary
prostate cancer.
In summary, we have presented evidence for a pros-
tate cancer susceptibility locus at 20q13, with the
strongest evidence among pedigrees without male-to-
male transmission. Following confirmation of this link-
age, we propose the designation HPC20 for the locus.
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